PortfoliosLab logo
IDYA vs. RXRX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between IDYA and RXRX is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

IDYA vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in IDEAYA Biosciences, Inc. (IDYA) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

-100.00%-50.00%0.00%50.00%December2025FebruaryMarchAprilMay
-6.39%
-86.17%
IDYA
RXRX

Key characteristics

Sharpe Ratio

IDYA:

-1.07

RXRX:

-0.54

Sortino Ratio

IDYA:

-1.89

RXRX:

-0.46

Omega Ratio

IDYA:

0.79

RXRX:

0.95

Calmar Ratio

IDYA:

-0.86

RXRX:

-0.56

Martin Ratio

IDYA:

-1.60

RXRX:

-1.54

Ulcer Index

IDYA:

37.07%

RXRX:

33.02%

Daily Std Dev

IDYA:

53.59%

RXRX:

93.10%

Max Drawdown

IDYA:

-74.64%

RXRX:

-90.39%

Current Drawdown

IDYA:

-63.04%

RXRX:

-89.52%

Fundamentals

Market Cap

IDYA:

$1.79B

RXRX:

$2.32B

EPS

IDYA:

-$3.36

RXRX:

-$1.80

PS Ratio

IDYA:

256.10

RXRX:

39.37

PB Ratio

IDYA:

1.73

RXRX:

2.07

Total Revenue (TTM)

IDYA:

$7.00M

RXRX:

$59.76M

Gross Profit (TTM)

IDYA:

$5.26M

RXRX:

-$46.00K

EBITDA (TTM)

IDYA:

-$274.69M

RXRX:

-$534.16M

Returns By Period

In the year-to-date period, IDYA achieves a -32.22% return, which is significantly higher than RXRX's -35.95% return.


IDYA

YTD

-32.22%

1M

10.39%

6M

-44.31%

1Y

-57.14%

5Y*

20.54%

10Y*

N/A

RXRX

YTD

-35.95%

1M

-6.88%

6M

-39.01%

1Y

-49.88%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

IDYA vs. RXRX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IDYA
The Risk-Adjusted Performance Rank of IDYA is 44
Overall Rank
The Sharpe Ratio Rank of IDYA is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of IDYA is 33
Sortino Ratio Rank
The Omega Ratio Rank of IDYA is 55
Omega Ratio Rank
The Calmar Ratio Rank of IDYA is 44
Calmar Ratio Rank
The Martin Ratio Rank of IDYA is 55
Martin Ratio Rank

RXRX
The Risk-Adjusted Performance Rank of RXRX is 1919
Overall Rank
The Sharpe Ratio Rank of RXRX is 2222
Sharpe Ratio Rank
The Sortino Ratio Rank of RXRX is 2525
Sortino Ratio Rank
The Omega Ratio Rank of RXRX is 2626
Omega Ratio Rank
The Calmar Ratio Rank of RXRX is 1616
Calmar Ratio Rank
The Martin Ratio Rank of RXRX is 66
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

IDYA vs. RXRX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for IDEAYA Biosciences, Inc. (IDYA) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current IDYA Sharpe Ratio is -1.07, which is lower than the RXRX Sharpe Ratio of -0.54. The chart below compares the historical Sharpe Ratios of IDYA and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.50December2025FebruaryMarchAprilMay
-1.07
-0.54
IDYA
RXRX

Dividends

IDYA vs. RXRX - Dividend Comparison

Neither IDYA nor RXRX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

IDYA vs. RXRX - Drawdown Comparison

The maximum IDYA drawdown since its inception was -74.64%, smaller than the maximum RXRX drawdown of -90.39%. Use the drawdown chart below to compare losses from any high point for IDYA and RXRX. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%-30.00%December2025FebruaryMarchAprilMay
-63.04%
-89.52%
IDYA
RXRX

Volatility

IDYA vs. RXRX - Volatility Comparison

The current volatility for IDEAYA Biosciences, Inc. (IDYA) is 20.37%, while Recursion Pharmaceuticals, Inc. (RXRX) has a volatility of 36.48%. This indicates that IDYA experiences smaller price fluctuations and is considered to be less risky than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%35.00%40.00%45.00%December2025FebruaryMarchAprilMay
20.37%
36.48%
IDYA
RXRX

Financials

IDYA vs. RXRX - Financials Comparison

This section allows you to compare key financial metrics between IDEAYA Biosciences, Inc. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00M25.00M30.00M202120222023202420250
14.75M
(IDYA) Total Revenue
(RXRX) Total Revenue
Values in USD except per share items